Valeant CEO: Deal will get done despite 'poison pill'

Wednesday, 23 Apr 2014 | 7:37 AM ET

J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.